CRVS
Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.39
−1.77%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -60.3%
- EPS
- +4.5%
- Free cash flow
- -56.1%
- Operating cash flow
- -54.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +15.0%
- EPS
- -38.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- +75.6%
- EBIT
- -56.0%
- Net income
- +75.5%
- EPS
- +81.4%
- Free cash flow
- -29.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026